Scholars@Duke
Carey Kernodle Anders

Carey Kernodle Anders

Professor of Medicine
Medicine, Medical Oncology
carey.anders@duke.edu
Box 3381, Seeley Mudd Building, Durham, NC 27710
Dept of Medicine, Durham, NC 27710

Scholarly Works

Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidence.

Journal article Breast · June 9, 2026 BACKGROUND: Recent years have seen rapid advances in human epidermal growth factor receptor 2 (HER2)-directed therapies for breast cancer. The shifting therapeutic landscape has presented patients and clinicians with a plethora of effective treatment optio ... Full text Link to item Cite

Trastuzumab deruxtecan (T-DXd) + durvalumab (D) in patients (pts) with previously untreated HER2+ unresectable/metastatic breast cancer (mBC): Final analysis from DESTINY-Breast07.

Journal article Journal of Clinical Oncology · June 1, 2026 1012Background: T-DXd is approved for adult pts with HER2+ mBC who received a prior anti-HER2–based regimen, or as 1L therapy when given in combination with pertuzumab (P). DESTINY-Breast07 (NCT04538742) is a Phase 1b/2, open-label, platform study explorin ... Full text Cite

Intracranial Progression-Free Survival Correlates with Overall Survival and Varies by Tumor Subtype in Patients with Breast Cancer and Brain Metastases.

Journal article Neuro Oncol · May 12, 2026 BACKGROUND: Brain metastases in patients with breast cancer (BCBM) are common. While the Breast Graded Prognostic Assessment (Breast GPA) predicts overall survival (OS), its ability to predict intracranial progression-free survival (icPFS) has not been est ... Full text Link to item Cite

DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.

Journal article Clin Cancer Res · March 16, 2026 PURPOSE: Establish the safety, tolerability, and preliminary activity of trastuzumab deruxtecan (T-DXd) in combination with other anticancer therapies in human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer (mBC). PATIENTS AND METHO ... Full text Link to item Cite

Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer.

Journal article NPJ Precis Oncol · March 13, 2026 Trastuzumab deruxtecan (T-DXd) is commonly used for treating metastatic breast cancer (MBC); however, traditional HER2 immunohistochemistry has largely failed to predict T-DXd activity. We reviewed survival outcomes and tested the reliability of multiple H ... Full text Link to item Cite

Intracranial metastases from solid tumors: Call to action and consensus from the Society for Neuro-Oncology and American Society of Clinical Oncology collaborative.

Journal article Neuro Oncol · February 1, 2026 Intracranial metastases (ICM), specifically parenchymal brain metastases, remain a major clinical challenge in solid tumor oncology, despite recent advances in cancer therapies which have led to improvements in survival for these patients. Improving outcom ... Full text Link to item Cite

The evolving landscape of brain metastasis: volume II.

Journal article Trends Cancer · February 2026 Brain metastasis (BrM) represents the most common intracranial malignancy, arising in up to 30% of all adult cancer patients and contributing significantly to cancer-related morbidity and mortality. BrM is now recognized as a biologically distinct conditio ... Full text Link to item Cite

Novel treatment strategies and key research priorities for patients with breast cancer and central nervous system (CNS) metastases.

Journal article NPJ Breast Cancer · December 20, 2025 Despite improvements in surgical techniques, advances in delivery of radiation therapy, and development of therapies with central nervous system (CNS) activity, the presence of CNS metastases from breast cancer is frequently associated with a poor prognosi ... Full text Link to item Cite

Evaluation of efficacy and safety of sequential antibody drug conjugates (ADCs) in human epidermal growth factor 2 (HER2)-negative metastatic breast cancer.

Journal article Breast Cancer Res Treat · December 2025 PURPOSE: Limited data is available assessing sequencing of antibody drug conjugates (ADCs) in patients with hormone receptor-positive (HR +), human epidermal growth factor 2 (HER2)-negative, HER2-low, and triple-negative metastatic breast cancer (MBC), inc ... Full text Link to item Cite

Management outcomes for biopsy-proven radiation necrosis in patients with brain metastases in the era of immune-checkpoint blockade.

Journal article J Neurooncol · October 2025 PURPOSE: Immunotherapy and stereotactic radiosurgery (SRS) are frequently combined in the management of brain metastases from non-small cell lung cancer (NSCLC) and melanoma. However, concurrent SRS and dual immune-checkpoint inhibition (ICPI) elevate the ... Full text Open Access Link to item Cite

Real-world treatment patterns and clinical outcomes with tucatinib-based therapy in patients with HER2-positive metastatic breast cancer: analyses of two nationwide administrative health claims databases.

Journal article Int J Clin Oncol · October 2025 PURPOSE: To describe real-world characteristics and clinical outcomes among patients with HER2+ MBC receiving tucatinib-based treatments. METHODS: This retrospective study included patients diagnosed with HER2+ MBC between January 2017 and December 2022 fr ... Full text Link to item Cite

Atopy Improves Survival and Decreases Risk of Brain Metastasis in Cutaneous Melanoma.

Journal article Cancer Epidemiol Biomarkers Prev · September 2, 2025 BACKGROUND: Development of new melanoma therapies has increased survival, and more patients are living to develop brain metastasis (BrM). Identifying those at increased risk of BrM is of significant public health importance, and our objective was to assess ... Full text Link to item Cite

Table S6 from Atopy Improves Survival and Decreases Risk of Brain Metastasis in Cutaneous Melanoma

Other · September 2, 2025 <p>Table S6 provides results by timing of brain metastasis (at diagnosis or after diagnosis)</p> ... Full text Cite

Table S2 from Atopy Improves Survival and Decreases Risk of Brain Metastasis in Cutaneous Melanoma

Other · September 2, 2025 <p>Table S2 shows codes used to classify therapies</p> ... Full text Cite

Figure S4 from Atopy Improves Survival and Decreases Risk of Brain Metastasis in Cutaneous Melanoma

Other · September 2, 2025 <p>Figure S4 shows sex-specific hazard of death based on atopic trait</p> ... Full text Cite

Table S3 from Atopy Improves Survival and Decreases Risk of Brain Metastasis in Cutaneous Melanoma

Other · September 2, 2025 <p>Table S3 provides an overview of characteristics of included individuals by atopic disease status</p> ... Full text Cite

Figure S2 from Atopy Improves Survival and Decreases Risk of Brain Metastasis in Cutaneous Melanoma

Other · September 2, 2025 <p>Figure S2 shows the correlation between atopic conditions and other prognostic variables</p> ... Full text Cite

Figure S5 from Atopy Improves Survival and Decreases Risk of Brain Metastasis in Cutaneous Melanoma

Other · September 2, 2025 <p>Figure S5 shows probability of brain metastasis free survival by atopic trait</p> ... Full text Cite

Table S7 from Atopy Improves Survival and Decreases Risk of Brain Metastasis in Cutaneous Melanoma

Other · September 2, 2025 <p>Table S7 provides results for those without metastatic disease at diagnosis</p> ... Full text Cite

Table S5 from Atopy Improves Survival and Decreases Risk of Brain Metastasis in Cutaneous Melanoma

Other · September 2, 2025 <p>Table S5 provides adjusted results from survival and cumulative incidence analyses</p> ... Full text Cite

Data from Atopy Improves Survival and Decreases Risk of Brain Metastasis in Cutaneous Melanoma

Other · September 2, 2025 <div>AbstractBackground:<p>Development of new melanoma therapies has increased survival, and more patients are living to develop brain metastasis (BrM). Identifying those at increased risk of BrM is of significant public health importan ... Full text Cite

Table S1 from Atopy Improves Survival and Decreases Risk of Brain Metastasis in Cutaneous Melanoma

Other · September 2, 2025 <p>Table S1 shows codes used to classify atopic disease types</p> ... Full text Cite

Figure S3 from Atopy Improves Survival and Decreases Risk of Brain Metastasis in Cutaneous Melanoma

Other · September 2, 2025 <p>Figure S3 shows association between atopic traits and treatment choice</p> ... Full text Cite

Table S4 from Atopy Improves Survival and Decreases Risk of Brain Metastasis in Cutaneous Melanoma

Other · September 2, 2025 <p>Table S4 provides results from univariate survival and cumulative incidence analyses</p> ... Full text Cite

Figure S1 from Atopy Improves Survival and Decreases Risk of Brain Metastasis in Cutaneous Melanoma

Other · September 2, 2025 <p>Figure S1 illustrates the data filtering process used to build the analytic dataset</p> ... Full text Cite

Pregnancy and pregnancy outcomes after adolescent and young adult cancer in the AYA horizon study.

Journal article Int J Cancer · August 1, 2025 Lower birth rates and higher pregnancy loss are observed after childhood cancer. Studies specific to adolescent and young adult (AYA) cancer rarely have information on pregnancies that do not end in live birth, fertility preservation strategies, or detaile ... Full text Link to item Cite

Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium.

Other Clin Breast Cancer · August 2025 PURPOSE: Breast cancer is the most common type of cancer for women in the United States and accounts for nearly 25% of all cancers and 16% of cancer deaths worldwide. New treatment options continue to emerge offering improved management options for patient ... Full text Link to item Cite

A comprehensive, multi-center, immunogenomic analysis of melanoma brain metastases.

Journal article Acta Neuropathol Commun · June 2, 2025 BACKGROUND: Melanoma brain metastases (MBM) have a unique molecular profile compared to extracranial metastases (ECM). Description of the biological features and clinical outcomes of MBM will facilitate the design of rational therapies. METHODS: We examine ... Full text Link to item Cite

Genomic and immune profiling of breast cancer brain metastases.

Journal article Acta Neuropathol Commun · May 12, 2025 BACKGROUND: Brain metastases (BrM) arising from breast cancer (BC) are an increasing consequence of advanced disease, with up to half of patients with metastatic HER2 + or triple negative BC experiencing central nervous system (CNS) recurrence. The genomic ... Full text Link to item Cite

In vitro fertilization with cryopreserved oocytes or embryos after cancer: The role of gestational carriers.

Journal article Cancer · April 15, 2025 BACKGROUND: Fertility preservation counseling is recommended for reproductive-age cancer patients. Gestational carriers are individuals who carry a pregnancy for someone else. This service creates a path to biological children when cancer treatment necessi ... Full text Link to item Cite

Effect of Breast Cancer Receptor Subtypes and CSF Cytology Status on Survival of Patients With Leptomeningeal Disease.

Journal article Clin Breast Cancer · January 2025 BACKGROUND: It is unclear whether breast cancer (BC) subtypes or CSF cytology results are associated with overall survival (OS) among patients with BC leptomeningeal disease (LMD). This single-institution retrospective study compares OS among BC patients w ... Full text Link to item Cite

Results of a patient-level pooled analysis of three studies of trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastasis.

Journal article ESMO Open · January 2025 BACKGROUND: Brain metastases (BMs) are common in human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer, increasing morbidity and mortality. Systemic therapy for BMs can be effective, with the triple combination of trastuzumab, cap ... Full text Link to item Cite

Real-World Clinical Outcomes in Patients With HER2+ Metastatic Breast Cancer Receiving Tucatinib-Based Therapy After 2 or More Prior Metastatic HER2-Directed Regimens.

Journal article Cancer Control · 2025 Introduction: Tucatinib is an oral human epidermal growth factor receptor 2 (HER2)-targeted therapy approved by the European Medicines Agency (EMA) for use in combination with trastuzumab and capecitabine for patients with HER2 + locally advanced or metast ... Full text Link to item Cite

Consortium for Intracranial Metastasis Academic Research (CIMARa): Global interdisciplinary collaborations to improve outcomes of patient with brain metastases.

Journal article Neurooncol Adv · 2025 Brain metastases (BrM) arising from solid tumors is an ever-increasing and often devastating clinical challenge impacting hundreds of thousands of patients annually worldwide. As systemic anticancer therapies, and thus survival, improve, the risk for centr ... Full text Link to item Cite

A comprehensive, multi-center, immunogenomic analysis of melanoma brain metastases

Journal article Acta neuropathologica communications · January 2025 Cite

Impact of systemic therapy after stereotactic radiosurgery in patients with limited brain-only metastasis.

Journal article Neurooncol Adv · 2025 BACKGROUND: The impact of systemic therapy (ST) on outcomes for patients with brain-only metastases (BrM) in the absence of extracranial disease (ECD) is not well established. We compared outcomes between patients with BrM treated with stereotactic radiosu ... Full text Link to item Cite

Trial in progress: ENCORE—Multicenter prospective registry of sequential antibody drug conjugates (ADCs) in HER2 negative metastatic breast cancer (MBC) (TBCRC-067).

Journal article Journal of Clinical Oncology · January 1, 2025 Background: Antibody-drug conjugates (ADCs) have demonstrated substantial improvement in progression free survival (PFS) and overall survival (OS) in phase III clinical trials in patients with metastatic triple negative breast cancer (mTNBC) and hormone re ... Full text Cite

A Phase I Trial of Alpelisib Combined With Capecitabine in Patients With HER2-Negative Metastatic Breast Cancer.

Journal article Clin Breast Cancer · December 2024 BACKGROUND: Alpelisib is an oral α-specific class I PI3K inhibitor approved in combination with fulvestrant for the treatment of PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast can ... Full text Link to item Cite

Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.

Journal article Nat Med · December 2024 Trastuzumab deruxtecan (T-DXd) intracranial activity has been observed in small or retrospective patient cohorts with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (mBC) and stable or active (untreated/previous ... Full text Link to item Cite

"Symptomatic" melanoma brain metastases: A call for clear definitions and adoption of standardized tools.

Journal article Eur J Cancer · September 2024 With improved systemic treatment and prolonged survival even with metastatic disease, diagnosing, treating, and monitoring brain metastases has become a central topic in the care of patients with melanoma. Patients with brain metastases from melanoma are t ... Full text Link to item Cite

Impact of systemic disease on CNS disease control after stereotactic radiosurgery to breast cancer brain metastases (The SYBRA Study).

Journal article NPJ Breast Cancer · August 2, 2024 The objective of the study is to assess impact of systemic disease (SD) status on overall survival and brain metastasis (BM) control, adopting a novel landmark approach to categorize SD among breast cancer (BC) patients. This single institution retrospecti ... Full text Link to item Cite

Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer.

Journal article Clin Cancer Res · April 1, 2024 PURPOSE: We explored the efficacy of PARP inhibition with or without programmed death ligand-1 (PD-L1) blockade as chemotherapy-free maintenance therapy for advanced triple-negative breast cancer (aTNBC) sensitive to platinum-based chemotherapy. PATIENTS A ... Full text Link to item Cite

Unique genomic alterations in the circulating tumor DNA of patients with solid tumors brain metastases.

Journal article Neurooncol Adv · 2024 BACKGROUND: Although serum circulating tumor DNA (ctDNA) is routine, data from patients with brain metastases (BrMs) is limited. We assessed genomic alterations in ctDNA from patients with solid tumor BrMs in 3 groups: Isolated BrMs with stable extracrania ... Full text Link to item Cite

DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC

Journal article Journal of Clinical Oncology · January 1, 2024 Background: Trastuzumab deruxtecan (T-DXd) is approved for adult patients (pts) with HER2+ advanced/metastatic breast cancer (mBC) who received a prior anti-HER2–based regimen. DESTINY-Breast07 is a Phase 1b/2 multicenter, open-label, modular study explori ... Full text Cite

Effect of breast cancer receptor subtypes and CSF cytology status on survival for patients with leptomeningeal disease

Journal article Journal of Clinical Oncology · January 1, 2024 Background: Leptomeningeal disease (LMD) in metastatic breast cancer (MBC) carries a poor prognosis. Data on the effect of BC sub types and CSF cytology results on overall survival (OS) are lacking. This single institution retrospective study compares OS a ... Full text Cite

Triple Negative Breast Cancer and Brain Metastases.

Journal article Clin Breast Cancer · December 2023 The treatment of metastatic breast cancer (MBC) has improved over the past decade, however prognosis continues to be mitigated by the fact that about 1 in 5 patients with MBC will develop brain metastases (BrM) during their metastatic disease course. 1 Thi ... Full text Link to item Cite

National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: challenges and recommended priorities.

Journal article Lancet Oncol · August 2023 Brain metastases are an increasing global public health concern, even as survival rates improve for patients with metastatic disease. Both metastases and the sequelae of their treatment are key determinants of the inter-related priorities of patient surviv ... Full text Link to item Cite

Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors.

Journal article J Immunol · July 15, 2023 Previous work from our group and others has shown that patients with breast cancer can generate a T cell response against specific human epidermal growth factor 2 (HER2) epitopes. In addition, preclinical work has shown that this T cell response can be aug ... Full text Link to item Cite

Available Systemic Treatments and Emerging Therapies for Breast Cancer Brain Metastases.

Journal article Curr Treat Options Oncol · June 2023 In 2023, breast cancer brain metastases (BCBrM) remain a major clinical challenge gaining well-deserved attention. Historically managed with local therapies alone, systemic therapies including small molecule inhibitors and antibody-drug conjugates (ADCs) h ... Full text Link to item Cite

The Enduring Effects of COVID for Cancer Care: Learning from Real-Life Clinical Practice.

Journal article Clin Cancer Res · May 1, 2023 For three years, COVID-19 has circulated among our communities and around the world, fundamentally changing social interactions, health care systems, and service delivery. For people living with (and receiving treatment for) cancer, pandemic conditions pre ... Full text Open Access Link to item Cite

Impact of prior systemic therapy on lymphocytic infiltration in surgically resected breast cancer brain metastases.

Journal article Breast Cancer Res Treat · May 2023 PURPOSE: Tumor-infiltrating lymphocytes (TILs) have been positively correlated with response to systemic therapy for triple-negative and HER2 + subtypes and improved clinical outcomes in early breast cancer (BC). Less is known about TILs in metastatic site ... Full text Link to item Cite

Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases.

Journal article Clin Cancer Res · April 14, 2023 PURPOSE: Preclinical data showed that prophylactic, low-dose temozolomide (TMZ) significantly prevented breast cancer brain metastasis. We present results of a phase I trial combining T-DM1 with TMZ for the prevention of additional brain metastases after p ... Full text Link to item Cite

Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference.

Journal article Lancet Oncol · April 2023 Successful drug development for people with cancers of the CNS has been challenging. There are multiple barriers to successful drug development including biological factors, rarity of the disease, and ineffective use of clinical trials. Based upon a series ... Full text Link to item Cite

Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan.

Journal article NPJ Breast Cancer · March 30, 2023 Leptomeningeal metastases (LM) are a devastating complication of HER2 + metastatic breast cancer (MBC), with no effective treatments. In a case series of 8 patients with heavily pretreated HER2 + MBC and progressing LM, all 8 patients (100%) derived clinic ... Full text Link to item Cite

Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.

Journal article JAMA Oncol · February 1, 2023 IMPORTANCE: It is estimated that up to 50% of patients with ERBB2 (HER2)-positive metastatic breast cancer (MBC) will develop brain metastases (BMs), which is associated with poor prognosis. Previous reports of the HER2CLIMB trial have demonstrated that tu ... Full text Link to item Cite

Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.

Journal article Lancet Oncol · February 2023 BACKGROUND: Poly(ADP-ribose) polymerase (PARP) inhibitors are effective in germline BRCA1 or BRCA2 (BRCA1/2) mutation-associated metastatic breast cancer. However, studies evaluating PARP inhibitors plus platinum-based chemotherapy in germline BRCA1/2-wild ... Full text Link to item Cite

Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases.

Journal article Clin Cancer Res · January 4, 2023 PURPOSE: Brain metastases can occur in up to 50% of patients with metastatic HER2-positive breast cancer. Because patients with active brain metastases were excluded from previous pivotal clinical trials, the central nervous system (CNS) activity of the an ... Full text Link to item Cite

Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2 + breast cancer.

Conference Breast Cancer Res Treat · January 2023 PURPOSE: Current systemic therapy guidelines for patients with HER2 + breast cancer brain metastases (BCBrM) diverge based on the status of extracranial disease (ECD). An in-depth understanding of the impact of ECD on outcomes in HER2 + BCBrM has never bee ... Full text Link to item Cite

Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.

Journal article Nat Cancer · January 2023 The AURORA US Metastasis Project was established with the goal to identify molecular features associated with metastasis. We assayed 55 females with metastatic breast cancer (51 primary cancers and 102 metastases) by RNA sequencing, tumor/germline DNA exom ... Full text Link to item Cite

Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer.

Journal article Front Oncol · 2023 BACKGROUND: Tucatinib is an oral human epidermal growth factor receptor 2 (HER2)-directed therapy approved in combination with trastuzumab and capecitabine for use in patients with previously treated HER2+ metastatic breast cancer (MBC) with/without brain ... Full text Link to item Cite

Systemic Therapy Approaches for Breast Cancer Brain and Leptomeningeal Metastases.

Journal article Curr Treat Options Oncol · October 2022 Brain metastasis arising from breast cancer is associated with a poor prognosis. Various systemic chemotherapy and targeted therapies which are effective against breast cancer often fail to provide benefits against brain metastasis. This is mainly due to l ... Full text Link to item Cite

Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update.

Journal article J Clin Oncol · August 10, 2022 PURPOSE: To update evidence-based guideline recommendations to practicing oncologists and others on systemic therapy for patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer. METHODS: An Expert Panel conducted a tar ... Full text Link to item Cite

Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update.

Journal article J Clin Oncol · August 10, 2022 PURPOSE: To provide updated evidence- and consensus-based guideline recommendations to practicing oncologists and others on the management of brain metastases for patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer ... Full text Link to item Cite

Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial.

Journal article JAMA Oncol · July 1, 2022 IMPORTANCE: Patients with breast cancer and brain metastases (BM) have a poor prognosis and high clinical need for novel treatments; however, historically, studies have often excluded these patients. Although the BEACON study did not meet its primary end p ... Full text Link to item Cite

Systemic management of brain metastases in HER2+ breast cancer in 2022.

Journal article Clin Adv Hematol Oncol · May 2022 Up to half of all patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer will eventually acquire brain metastases (BrMs), which are associated with reduced overall survival and decreased quality of life. Although t ... Link to item Cite

HER2-positive breast cancer brain metastasis: A new and exciting landscape.

Journal article Cancer Rep (Hoboken) · April 2022 BACKGROUND: Brain metastases (BrM) incidence is 25% to 50% in women with advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Radiation and surgery are currently the main local treatment approaches for central nervous system (CN ... Full text Link to item Cite

Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer.

Journal article J Immunother Cancer · February 2022 PURPOSE: Triple negative breast cancer (TNBC) is characterized by the presence of immune cells in the tumor microenvironment, however, the response to single-agent immune checkpoint inhibitor (ICI) therapy is modest. Preclinical models have demonstrated th ... Full text Link to item Cite

Systemic Therapy Type and Timing Effects on Radiation Necrosis Risk in HER2+ Breast Cancer Brain Metastases Patients Treated With Stereotactic Radiosurgery.

Journal article Front Oncol · 2022 BACKGROUND: There is a concern that HER2-directed systemic therapies, when administered concurrently with stereotactic radiosurgery (SRS), may increase the risk of radiation necrosis (RN). This study explores the impact of timing and type of systemic thera ... Full text Link to item Cite

Comprehensive Analysis of the Immunogenomics of Triple-Negative Breast Cancer Brain Metastases From LCCC1419.

Journal article Front Oncol · 2022 BACKGROUND: Triple negative breast cancer (TNBC) is an aggressive variant of breast cancer that lacks the expression of estrogen and progesterone receptors (ER and PR) and HER2. Nearly 50% of patients with advanced TNBC will develop brain metastases (BrM), ... Full text Link to item Cite

Multiplatform Analysis of Primary and Metastatic Breast Tumors from the AURORA US Network identifies microenvironment and epigenetics drivers of metastasis

Preprint · 2022 AbstractPatients with metastatic breast cancer (MBC) typically have short survival times and their successful treatment represents one of most challenging aspects of patient care. This poor prognostic behavior is in part due to molecula ... Full text Cite

Cytotoxic Engineered Induced Neural Stem Cells as an Intravenous Therapy for Primary Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer.

Journal article Mol Cancer Ther · November 2021 Converting human fibroblasts into personalized induced neural stem cells (hiNSC) that actively seek out tumors and deliver cytotoxic agents is a promising approach for treating cancer. Herein, we provide the first evidence that intravenously-infused hiNSCs ... Full text Link to item Cite

Advances in the management of breast cancer brain metastases.

Journal article Neurooncol Adv · November 2021 The development of breast cancer (BC) brain metastases (BrM) is a common complication of advanced disease, occurring in up to half of the patients with advanced disease depending on the subtype. The management of BCBrM requires complex multidisciplinary ca ... Full text Link to item Cite

Inpatient palliative care utilization for patients with brain metastases.

Journal article Neurooncol Pract · August 2021 INTRODUCTION: Given the high symptom burden and complex clinical decision making associated with a diagnosis of brain metastases (BM), specialty palliative care (PC) can meaningfully improve patient quality of life. However, no prior study has formally eva ... Full text Link to item Cite

OTHR-14. An immunogenomic analysis of melanoma brain metastases (MBM) compared to extracranial metastases (ECM)

Journal article Neuro-oncology advances · August 2021 Abstract Background MBM have a unique molecular profile compared to ECM. Methods We analyzed a previously published dataset from MD Anderson Cancer Center, including RNA-seq on surgically resected, FFPE MBM and ECM from the same patients. ... Cite

OTHR-10. Diverse survival outcomes of HER2+ Breast Cancer Brain Metastases (BrCBM) presenting with isolated brain relapse compared to those with concurrent extracranial disease

Journal article Neuro-oncology advances · August 2021 Abstract Background In patients with isolated HER2+ BrCBM and no extracranial disease (ECD), there are no consensus guidelines on optimal treatment approaches following CNS-directed therapy. Our goal was to determine the implications of ECD at tim ... Cite

Development of next-generation tumor-homing induced neural stem cells to enhance treatment of metastatic cancers.

Journal article Sci Adv · June 2021 Engineered tumor-homing neural stem cells (NSCs) have shown promise in treating cancer. Recently, we transdifferentiated skin fibroblasts into human-induced NSCs (hiNSC) as personalized NSC drug carriers. Here, using a SOX2 and spheroidal culture-based rep ... Full text Link to item Cite

Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance).

Journal article JNCI Cancer Spectr · June 2021 BACKGROUND: Obesity and inactivity are associated with increased risk of cancer-related and overall mortality in breast cancer, but there are few data in metastatic disease. METHODS: Cancer and Leukemia Group B 40502 was a randomized trial of first-line ta ... Full text Link to item Cite

Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.

Journal article Curr Treat Options Oncol · March 20, 2021 Immune checkpoint blockade (ICB) has revolutionized the treatment landscape across multiple solid tumor types. In triple-negative breast cancer (TNBC), clinical benefit for the addition of ICB to chemotherapy has been shown in both the metastatic and early ... Full text Link to item Cite

Salting the Soil: Targeting the Microenvironment of Brain Metastases.

Journal article Mol Cancer Ther · March 2021 Paget's "seed and soil" hypothesis of metastatic spread has acted as a foundation of the field for over a century, with continued evolution as mechanisms of the process have been elucidated. The central nervous system (CNS) presents a unique soil through t ... Full text Link to item Cite

Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase.

Journal article Breast Cancer Res Treat · February 2021 PURPOSE: Metastatic breast cancer (mBC) remains incurable and is associated with low survival rates. This study assessed the efficacy and safety of liposomal irinotecan in heavily pretreated patients with mBC, with or without active brain metastases (BM). ... Full text Link to item Cite

A case report of microsatellite instability (MSI)-high, HER2 amplified pancreatic adenocarcinoma with central nervous system metastasis.

Journal article AME Case Rep · 2021 Pancreatic adenocarcinoma commonly presents as metastatic disease and harbors a dire prognosis due to its aggressive behavior, propensity for resistance to therapies, and lack of targetable driver mutations. Additionally, despite advances in other cancers, ... Full text Link to item Cite

Outcomes in Patients With 4 to 10 Brain Metastases Treated With Dose-Adapted Single-Isocenter Multitarget Stereotactic Radiosurgery: A Prospective Study.

Journal article Adv Radiat Oncol · 2021 PURPOSE: To examine the effectiveness and safety of single-isocenter multitarget stereotactic radiosurgery using a volume-adapted dosing strategy in patients with 4 to 10 brain metastases. METHODS AND MATERIALS: Adult patients with 4 to 10 brain metastases ... Full text Link to item Cite

A Need for More Molecular Profiling in Brain Metastases.

Journal article Front Oncol · 2021 As local disease control improves, the public health impact of brain metastases (BrM) continues to grow. Molecular features are frequently different between primary and metastatic tumors as a result of clonal evolution during neoplasm migration, selective ... Full text Link to item Cite

Neuropathy

Book section · January 1, 2021 Peripheral neuropathy is commonly seen in breast cancer patients both actively receiving care and breast cancer survivors. Both short-term and long-term neuropathy can have a profound impact on quality of life during survivorship. Surgical and systemic tre ... Full text Cite

Effects of Breast Cancer Adjuvant Chemotherapy Regimens on Expression of the Aging Biomarker, p16INK4a.

Journal article JNCI Cancer Spectr · December 2020 BACKGROUND: Although chemotherapy saves lives, increasing evidence shows that chemotherapy accelerates aging. We previously demonstrated that mRNA expression of p16INK4a , a biomarker of senescence and molecular aging, increased early and dramatically afte ... Full text Link to item Cite

EXTH-02. TUMOR-HOMING INDUCED NEURAL STEM CELL THERAPY INHIBITS THE PROGRESSION OF BREAST CANCER BRAIN METASTASIS AND LEPTOMENINGEAL CARCINOMATOSIS

Journal article Neuro-oncology · November 2020 Abstract INTRODUCTION Breast cancer brain metastasis, including leptomeningeal carcinomatosis (LC), remains one of the most lethal CNS diseases. New therapies are urgently needed to treat this highly aggressive disease. Here we used models of both ... Cite

Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines.

Journal article Cancer Res · October 15, 2020 Spread of cancer to the brain remains an unmet clinical need in spite of the increasing number of cases among patients with lung, breast cancer, and melanoma most notably. Although research on brain metastasis was considered a minor aspect in the past due ... Full text Link to item Cite

A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer.

Journal article Clin Cancer Res · October 15, 2020 PURPOSE: The primary objective was to evaluate intracranial objective response rate (iORR) in patients receiving abemaciclib with brain or leptomeningeal metastases (LM) secondary to hormone receptor-positive (HR+) metastatic breast cancer (MBC). Secondary ... Full text Link to item Cite

Clinicopathologic features of breast cancer reclassified as HER2-amplified by fluorescence in situ hybridization with alternative chromosome 17 probes.

Journal article Ann Diagn Pathol · October 2020 OBJECTIVE: Dual probe fluorescence in situ hybridization (FISH) assays for determination of human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer provide a ratio of HER2 to chromosome 17. The ratio may be skewed by copy number ... Full text Link to item Cite

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.

Journal article J Clin Oncol · August 10, 2020 PURPOSE: In the HER2CLIMB study, patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer with brain metastases (BMs) showed statistically significant improvement in progression-free survival (PFS) with tucatinib. We describe ex ... Full text Link to item Cite

52. BrMPANEL: A PUBLIC RESOURCE OF ORGANOTROPIC CELL LINES

Journal article Neuro-oncology advances · August 2020 Abstract Central nervous system (CNS), notably brain, metastases are most prevalent in lung cancer (20–56% of patients), breast cancer (5–20%) and melanoma (7–16%). Lesions occur in both the brain parenchyma and the meninges. To mechanistically understand ... Cite

53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB)

Journal article Neuro-oncology advances · August 2020 Abstract BACKGROUND HER2CLIMB (NCT02614794) primary results have been reported previously (Murthy, NEJM 2019). We report results of exploratory efficacy analyses in pts with brain metastases (BM). METHODS All HER2+ MBC pts enrolled had a ... Cite

56. TUMOR-HOMING STEM CELL THERAPY INHIBITS THE PROGRESSION OF BREAST CANCER LEPTOMENINGEAL CARCINOMATOSIS

Journal article Neuro-oncology advances · August 2020 Abstract INTRODUCTION Leptomeningeal carcinomatosis remains one of the most lethal forms of central nervous system metastasis, with a median survival of only 4 months. Effective new therapies are urgently needed to treat this highly aggressive can ... Cite

ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases.

Journal article Clin Cancer Res · June 15, 2020 PURPOSE: ANG1005, a novel taxane derivative, consists of three paclitaxel molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via LRP1 transport system. Preclinical ... Full text Link to item Cite

What's the Price? Toxicities of Targeted Therapies in Breast Cancer Care.

Journal article Am Soc Clin Oncol Educ Book · May 2020 Agents with mechanisms novel to breast cancer care have been approved to treat breast cancer. These agents include drugs that target cyclin-dependent kinases, phosphoinositide 3-kinase PI3KCA gene mutations, PARP, checkpoint regulation, and novel antibody- ... Full text Link to item Cite

Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022.

Journal article Clin Breast Cancer · April 2020 PURPOSE: This pilot study was performed to test our ability to administer neratinib monotherapy before clinically recommended craniotomy in patients with HER2-positive metastatic breast cancer to the central nervous system, to examine neratinib's central n ... Full text Link to item Cite

Current multidisciplinary management of brain metastases.

Journal article Cancer · April 1, 2020 Brain metastasis (BM), the most common adult brain tumor, develops in 20% to 40% of patients with late-stage cancer and traditionally are associated with a poor prognosis. The management of patients with BM has become increasingly complex because of new an ... Full text Link to item Cite

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

Journal article N Engl J Med · February 13, 2020 BACKGROUND: Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. Tucatinib is an investigational, oral, ... Full text Link to item Cite

Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2- Breast Cancer.

Journal article Clin Breast Cancer · February 2020 Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with backbone endocrine therapy have markedly improved progression-free survival and overall survival over endocrine therapy alone in advanced hormone receptor-positive, HER2-negative (HR+/HER ... Full text Link to item Cite

The Promise of Immunotherapy for Breast Cancer Brain Metastases

Journal article Current Breast Cancer Reports · December 1, 2019 Purpose of Review: The goal of our review is to describe the rationale for immunotherapy in the treatment of breast cancer brain metastases (BCBM), the current landscape of clinical trials for this disease process, and possible future directions based on a ... Full text Cite

The Evolving Modern Management of Brain Metastasis.

Journal article Clin Cancer Res · November 15, 2019 The incidence of brain metastases is increasing as cancer therapies improve and patients live longer, providing new challenges to the multidisciplinary teams that care for these patients. Brain metastatic cancer cells possess unique characteristics that al ... Full text Link to item Cite

SCIDOT-22. INTRACEREBROVENTRICULAR DELIVERY OF TUMOR-HOMING CYTOTOXIC HUMAN INDUCED NEURAL STEM CELLS FOR TREATMENT OF BRAIN METASTASES

Journal article Neuro-oncology · November 2019 Abstract INTRODUCTION Non-small cell lung cancer (NSCLC) and breast cancer are the most common cancers that metastasize to the brain. New therapies are needed to target and eradicate metastases. We have developed genetically-engineered induced neu ... Cite

Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors.

Journal article J Immunother Cancer · October 18, 2019 The interplay between the immune system and tumor progression is well recognized. However, current human breast cancer immunophenotyping studies are mostly focused on primary tumors with metastatic breast cancer lesions remaining largely understudied. To a ... Full text Link to item Cite

Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice.

Journal article Cancer · September 1, 2019 BACKGROUND: In the current study, the authors investigated the incidence of moderate to severe chemotherapy-induced peripheral neuropathy (CIPN) for chemotherapy regimens commonly used in current clinical practice for the treatment of patients with early b ... Full text Link to item Cite

TRLS-06. PHASE 1 EXPANSION STUDY OF IRINOTECAN LIPOSOME INJECTION (nal-IRI) IN PATIENTS WITH METASTATIC BREAST CANCER (mBC): FINDINGS FROM THE COHORT WITH ACTIVE BRAIN METASTASIS (BM)

Journal article Neuro-oncology advances · August 2019 Abstract BACKGROUND: nal-IRI is a liposomal formulation of irinotecan (topoisomerase-1 inhibitor). Preclinical data show that nal-IRI accumulates in BMs and prolongs survival in animal models of BM. Findings from a phase 1 expansion study (NCT01770353), ev ... Cite

THER-06. GENOMIC AND IMMUNE CHARACTERIZATION OF TRIPLE NEGATIVE BREAST CANCER BRAIN METASTASES

Journal article Neuro-oncology advances · August 2019 Abstract INTRODUCTION: Approximately 50% of patients with metastatic triple negative breast cancer (TNBC) will develop brain metastases (BM). Routinely treated with radiotherapy and/or surgery, survival is generally less than one year. There are no approve ... Cite

THER-15. DEVELOPING TUMOR-HOMING CYTOTOXIC HUMAN INDUCED NEURAL STEM CELL THERAPY FOR BRAIN METASTASES

Journal article Neuro-oncology advances · August 2019 Abstract INTRODUCTION: Non-small cell lung cancer (NSCLC) and breast cancer are the most common cancers that metastasize to the brain. New therapies are needed to seek out and eradicate metastases. Genetically engineered neural stem cells (NSCs) have shown ... Cite

TRLS-10. MITIGATING NEUROCOGNITIVE DEFICITS FROM WHOLE-BRAIN RADIOTHERAPY IN PATIENTS WITH NUMEROUS BRAIN METASTASES VIA A NOVEL SUPEROXIDE DISMUTASE MIMETIC: RATIONALE & DESIGN OF A CLINICAL TRIAL

Journal article Neuro-oncology advances · August 2019 Abstract BACKGROUND: Patients with a large number of brain metastases (BM) and/or micrometastatic disease in the brain present a clinical challenge. While technical innovations in stereotactic radiosurgery (SRS) have extended the number of BM that can be e ... Cite

BSCI-22. IDENTIFICATION OF ACTIONABLE TYROSINE KINASE-REGULATED NETWORKS REQUIRED FOR LUNG AND BREAST CANCER BRAIN METASTASIS

Journal article Neuro-oncology advances · August 2019 Abstract Brain metastases are a common consequence of advanced lung and breast cancer resulting in functional impairment, cranial neuropathies, and decline in quality of life. Current therapies for brain metastasis, such as whole brain radiation therapy, c ... Cite

Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.

Journal article JAMA Oncol · August 1, 2019 IMPORTANCE: Poly(adenosine diphosphate-ribose) polymerase inhibitor and anti-programmed death receptor-1 inhibitor monotherapy have shown limited clinical activity in patients with advanced triple-negative breast cancer (TNBC). OBJECTIVE: To evaluate the c ... Full text Link to item Cite

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.

Journal article J Clin Oncol · August 1, 2019 PURPOSE: To update the American Society of Clinical Oncology endorsement of the Cancer Care Ontario recommendations on the Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer. METHODS: Tw ... Full text Link to item Cite

Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases.

Journal article Breast Cancer Res Treat · July 2019 PURPOSE: Brain metastases (BM) are a complication of advanced breast cancer (BC). Histology of melanoma BM offers prognostic value; however, understanding the microenvironment of breast cancer brain metastases (BCBM) is less characterized. This study repor ... Full text Link to item Cite

ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.

Journal article Future Oncol · July 2019 The increasing incidence of breast cancer brain metastases is a major clinical problem with its associated poor prognosis and limited treatment options. The long-acting topoisomerase-1 inhibitor, etirinotecan pegol, was designed to preferentially accumulat ... Full text Link to item Cite

Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer.

Journal article Oncologist · June 2019 BACKGROUND: This study explores the incidence of patient-reported major toxicity-symptoms rated "moderate," "severe," or "very severe"-for chemotherapy regimens commonly used in early breast cancer. PATIENTS AND METHODS: Female patients aged 21 years or ol ... Full text Link to item Cite

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

Journal article J Clin Oncol · May 1, 2019 PURPOSE: Evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)-positive breast cancer to the CNS are limited. We previously reported modest activity of neratinib monotherapy for HER2-positive breast cancer brain metastas ... Full text Link to item Cite

Brain metastases.

Journal article Nat Rev Dis Primers · January 17, 2019 An estimated 20% of all patients with cancer will develop brain metastases, with the majority of brain metastases occurring in those with lung, breast and colorectal cancers, melanoma or renal cell carcinoma. Brain metastases are thought to occur via seedi ... Full text Link to item Cite

Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models.

Journal article Neurooncol Adv · 2019 BACKGROUND: Despite the poor prognosis of triple-negative breast cancer (TNBC) brain metastases, there are no approved systemic therapies. We explored the DNA-damaging poly(ADP-ribose) polymerase inhibitor (PARPi) niraparib in intracranial mouse models of ... Full text Link to item Cite

Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors

Preprint · 2019 The interplay between the immune system and tumor progression is well recognized. However, current human breast cancer immunophenotyping studies are mostly focused on primary tumors with metastatic breast cancer lesions remaining largely understudied. To a ... Full text Cite

Correction to: Measuring and understanding adherence in a home-based exercise intervention during chemotherapy for early breast cancer.

Journal article Breast Cancer Res Treat · January 2019 In the original publication, the sixth author name was published incorrectly as A. Wood. The correct author name should read as W. A. Wood. ... Full text Link to item Cite

Breast cancer in adolescents and young adults.

Journal article Pediatr Blood Cancer · December 2018 Breast cancer is the most common cancer of adolescents and young adult (AYA) women aged 15 to 39 years, accounting for 5.6% of all invasive breast cancer in women. In comparison with older women, AYAs are more likely to have familial cancer predisposition ... Full text Link to item Cite

Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ

Journal article Npj Breast Cancer · December 1, 2018 Serial monitoring of plasma DNA mutations in estrogen receptor positive metastatic breast cancer (ER + MBC) holds promise as an early predictor of therapeutic response. Here, we developed dPCR-SEQ, a customized assay that utilizes digital PCR-based target ... Full text Cite

Dual HER2-Targeting in the Adjuvant Setting: Where We Have Been and Where We Are Going.

Journal article Oncology (Williston Park) · October 15, 2018 Adjuvant human epidermal growth factor receptor 2 (HER2)-directed treatment has changed dramatically over the past decade. Historically, the addition of 1 year of trastuzumab to adjuvant chemotherapy has significantly improved both disease-free survival an ... Link to item Cite

LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.

Journal article Breast Cancer Res Treat · October 2018 PURPOSE: HER2 + breast cancer (BC) is an aggressive subtype with high rates of brain metastases (BCBM). Two-thirds of HER2 + BCBM demonstrate activation of the PI3K/mTOR pathway driving resistance to anti-HER2 therapy. This phase II study evaluated everoli ... Full text Link to item Cite

A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.

Journal article Clin Breast Cancer · August 2018 BACKGROUND: Buparlisib is an oral pan-class I phosphotidyinositol-3-kinase (PI3K) inhibitor. The present phase I study evaluated the safety, pharmacokinetics, and efficacy of buparlisib with capecitabine in patients with metastatic breast cancer. PATIENTS ... Full text Link to item Cite

Erratum: Multidisciplinary Management of Breast Cancer During Pregnancy.

Journal article Oncologist · June 2018 [This corrects the article DOI: 10.1634/theoncologist.2016-0208.]. ... Full text Link to item Cite

Live birth outcomes after adolescent and young adult breast cancer.

Journal article Int J Cancer · May 15, 2018 Reproductive outcomes are an important survivorship concern for women diagnosed with cancer as adolescents and young adults (AYAs). We examined the incidence of live birth and the prevalence of adverse birth outcomes according to tumor and treatment charac ... Full text Link to item Cite

Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies.

Journal article Ann Transl Med · May 2018 One of the most feared sequelae after a diagnosis of advanced breast cancer is development of metastases to the brain as this diagnosis can affect physical function, independence, relationships, quality of life, personality, and ultimately one's sense of s ... Full text Link to item Cite

Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer.

Journal article J Clin Invest · April 2, 2018 Breast cancer metastasis remains a clinical challenge, even within a single patient across multiple sites of the disease. Genome-wide comparisons of both the DNA and gene expression of primary tumors and metastases in multiple patients could help elucidate ... Full text Link to item Cite

Measuring and understanding adherence in a home-based exercise intervention during chemotherapy for early breast cancer.

Journal article Breast Cancer Res Treat · February 2018 PURPOSE: Ensuring and measuring adherence to prescribed exercise regimens are fundamental challenges in intervention studies to promote exercise in adults with cancer. This study reports exercise adherence in women who were asked to walk 150 min/week throu ... Full text Link to item Cite

Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies.

Journal article Clin Breast Cancer · February 2018 BACKGROUND: Given the wide adoption of human epidermal growth factor receptor 2 (HER2)-targeted therapies for advanced HER2-positive breast cancer, we studied the natural history of patients with HER2-positive breast cancer brain metastases (BCBM) over tim ... Full text Link to item Cite

Biology and Etiology of Young-Onset Breast Cancers among Premenopausal African American Women: Results from the AMBER Consortium.

Journal article Cancer Epidemiol Biomarkers Prev · December 2017 Background: African American (AA) women have higher incidence of aggressive, young-onset (<40 years) breast cancers. Young- and older-onset disease may have distinct tumor biologies and etiologies; however, studies investigating age differences among AA wo ... Full text Link to item Cite

Systemic Therapy in the Setting of Central Nervous System (CNS) Metastases in Breast Cancer

Journal article Current Breast Cancer Reports · December 1, 2017 Purpose of Review: Over 25% of patients with metastatic breast cancer will develop brain metastases. Recent advances in systemic therapy, especially molecularly targeted agents, have improved control of extracranial disease, but have had limited effect on ... Full text Cite

Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.

Journal article Neuro Oncol · October 19, 2017 BACKGROUND: Triple-negative breast cancer (TNBC), lacking expression of hormone and human epidermal growth factor receptor 2 receptors, is an aggressive subtype that frequently metastasizes to the brain and has no FDA-approved systemic therapies. Previous ... Full text Link to item Cite

Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.

Journal article Neuro Oncol · October 19, 2017 BACKGROUND: Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Prognosis remains poor despite multimodal therapy. Developing alternative treatments is essential. Drugs targeting kinases within the phosphoinositide 3-kinase (PI3K) and ... Full text Link to item Cite

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.

Journal article Clin Cancer Res · October 1, 2017 Purpose: Based on promising preclinical data, we conducted a single-arm phase II trial to assess the clinical benefit rate (CBR) of neratinib, defined as complete/partial response (CR/PR) or stable disease (SD) ≥24 weeks, in HER2mut nonamplified metastatic ... Full text Link to item Cite

Discerning Clinical Responses in Breast Cancer Based On Molecular Signatures.

Journal article Am J Pathol · October 2017 Breast cancer represents a heterogeneous collection of diseases with disparate clinical behaviors, responses to treatment, and patient outcomes, despite common histopathological features at diagnosis. Examination of molecular signatures of breast cancer (b ... Full text Link to item Cite

Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer.

Journal article J Clin Invest · September 1, 2017 Claudin-low breast cancer is an aggressive subtype that confers poor prognosis and is found largely within the clinical triple-negative group of breast cancer patients. Here, we have shown that intrinsic and immune cell gene signatures distinguish the clau ... Full text Link to item Cite

Birth Outcomes Among Adolescent and Young Adult Cancer Survivors.

Journal article JAMA Oncol · August 1, 2017 IMPORTANCE: Cancer diagnosis and treatment may adversely affect reproductive outcomes among female cancer survivors. OBJECTIVE: To compare the birth outcomes of adolescent and young adult cancer survivors (AYA [diagnosed at ages 15-39 years]) with those of ... Full text Link to item Cite

The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.

Journal article Sci Transl Med · May 24, 2017 Although targeted therapies are often effective systemically, they fail to adequately control brain metastases. In preclinical models of breast cancer that faithfully recapitulate the disparate clinical responses in these microenvironments, we observed tha ... Full text Link to item Cite

Coordination of Care for Breast Reconstruction Patients: A Provider Survey.

Journal article Clin Breast Cancer · April 2017 OBJECTIVES: Communication between medical oncologists (MOs) and plastic surgeons (PSs) is important to optimize outcomes for patients with breast cancer seeking breast reconstruction. We sought to evaluate the knowledge MOs and PSs have of each others' fie ... Full text Link to item Cite

Multidisciplinary Management of Breast Cancer During Pregnancy.

Journal article Oncologist · March 2017 BACKGROUND: Although breast cancer during pregnancy (BCDP) is rare (occurring with only 0.4% of all BC diagnoses in female patients aged 16-49 years), management decisions are challenging to both the patient and the multidisciplinary team. MATERIALS AND ME ... Full text Link to item Cite

Breast Cancer Before 40

Book section · January 1, 2017 Approximately 6 % of women with breast cancer are diagnosed before the age of 40, and this disease accounts for more than 40 % of all cancers in women in this age group. Historically, survival rates are worse for younger women when compared to older women; ... Full text Cite

Endocrine therapy and urogenital outcomes among women with a breast cancer diagnosis.

Journal article Cancer Causes Control · November 2016 PURPOSE: Endocrine therapy for breast cancer can exacerbate menopausal symptoms. The association between endocrine therapy and common pelvic floor disorders including urinary incontinence has rarely been evaluated. We examined urogenital and sexual side ef ... Full text Link to item Cite

Multidisciplinary Management of Breast Cancer Brain Metastases.

Journal article Oncology (Williston Park) · October 15, 2016 This review summarizes the most up-to-date approach to the multidisciplinary management of patients with breast cancer brain metastases. A brief overview of the epidemiology and biology of breast cancer brain metastasis is provided. The perspectives of rad ... Link to item Cite

Management of brain metastases in breast cancer.

Journal article Clin Adv Hematol Oncol · September 2016 Link to item Cite

OS7.2 A Phase II Study of ANG1005, a novel BBB/BCB Penetratant Taxane in Patients with Recurrent Brain Metastases and Leptomeningeal Carcinomatosis from Breast Cancer

Journal article Neuro-oncology · September 2016 Abstract Introduction: Treatment options for brain metastases (BM) and leptomeningeal carcinomatosis (LC) are limited due to the inability of most anti-cancer agents to cross the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier ... Cite

Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the Carolina Breast Cancer Study: a case-control study.

Journal article Breast Cancer Res · August 4, 2016 BACKGROUND: Young-onset breast cancer (<40 years) is associated with worse prognosis and higher mortality. Breast cancer risk factors may contribute to distinct tumor biology and distinct age at onset, but understanding of these relationships has been hamp ... Full text Link to item Cite

Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT(®) nanoparticle formulation against non-small-cell lung cancer brain metastases.

Journal article Nanomedicine (Lond) · August 2016 AIM: Particle Replication in Nonwetting Templates (PRINT(®)) PLGA nanoparticles of docetaxel and acid-labile C2-dimethyl-Si-Docetaxel were evaluated with small molecule docetaxel as treatments for non-small-cell lung cancer brain metastases. MATERIALS & ME ... Full text Link to item Cite

Updates in the management of brain metastases.

Journal article Neuro Oncol · August 2016 The clinical management/understanding of brain metastases (BM) has changed substantially in the last 5 years, with key advances and clinical trials highlighted in this review. Several of these changes stem from improvements in systemic therapy, which have ... Full text Link to item Cite

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations.

Journal article J Clin Oncol · July 1, 2016 PURPOSE: An American Society of Clinical Oncology (ASCO) panel considered the Cancer Care Ontario (CCO) recommendations on the role of patient and disease factors in selecting adjuvant therapy for women with early-stage breast cancer for endorsement. METHO ... Full text Link to item Cite

Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma.

Journal article Cancer · April 1, 2016 Adolescent and young adult (AYA) patients with cancer have not attained the same improvements in overall survival as either younger children or older adults. One possible reason for this disparity may be that the AYA cancers exhibit unique biologic charact ... Full text Link to item Cite

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

Journal article J Clin Oncol · February 20, 2016 PURPOSE: Dual human epidermal growth factor receptor 2 (HER2) targeting can increase pathologic complete response rates (pCRs) to neoadjuvant therapy and improve progression-free survival in metastatic disease. CALGB 40601 examined the impact of dual HER2 ... Full text Link to item Cite

The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.

Journal article Am Soc Clin Oncol Educ Book · 2016 Triple-negative breast cancer (TNBC) is clinically defined as lacking expression of the estrogen receptor (ER), progesterone receptor (ER), and HER2. Historically, TNBC has been characterized by an aggressive natural history and worse disease-specific outc ... Full text Link to item Cite

ACTIVITY OF TRASTUZUMAB-EMTANSINE (TDM1) IN HER2-POSITIVE BREAST CANCER BRAIN METASTASES: A CASE SERIES.

Journal article Cancer Treat Commun · 2016 The incidence of breast cancer brain metastasis (BCBM) is increasing due in part to improved management of systemic disease and prolonged survival. Despite this growing population of patients, there exists little consensus for the treatment of HER2-positiv ... Full text Link to item Cite

Use of Susceptibility-Weighted Imaging (SWI) in the Detection of Brain Hemorrhagic Metastases from Breast Cancer and Melanoma.

Journal article J Comput Assist Tomogr · 2016 PURPOSE: Susceptibility-weighted imaging (SWI) has significantly increased our sensitivity in detecting hemorrhagic brain lesions. We sought to explore the prevalence of intratumoral hemorrhage as detected by SWI in brain metastases from melanoma and breas ... Full text Link to item Cite

A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience.

Journal article Oncologist · January 2016 BACKGROUND: Breast cancer brain metastasis (BCBM) confers a poor prognosis and is unusual in requiring multidisciplinary care in the metastatic setting. The University of North Carolina at Chapel Hill (UNC-CH) has created a BCBM clinic to provide medical a ... Full text Link to item Cite

Gene expression in "young adult type" breast cancer: a retrospective analysis.

Journal article Oncotarget · May 30, 2015 BACKGROUND: Young women with breast cancer experience inferior outcome and commonly manifest aggressive biological subtypes. Data is controversial regarding biological differences between breast tumors in young (diagnosed at <40 years of age) versus older ... Full text Link to item Cite

Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer.

Journal article Mol Cancer Ther · April 2015 Patients with breast cancer brain metastases have extremely limited survival and no approved systemic therapeutics. Triple-negative breast cancer (TNBC) commonly metastasizes to the brain and predicts poor prognosis. TNBC frequently harbors BRCA mutations ... Full text Link to item Cite

Race, response to chemotherapy, and outcome within clinical breast cancer subtypes.

Journal article Breast Cancer Res Treat · April 2015 The effect of race on breast cancer outcome is confounded by tumor and treatment heterogeneity. We examined a cohort of women with stage II-III breast cancer treated uniformly with neoadjuvant chemotherapy to identify factors associated with racial differe ... Full text Link to item Cite

Local iontophoretic administration of cytotoxic therapies to solid tumors.

Journal article Sci Transl Med · February 4, 2015 Parenteral and oral routes have been the traditional methods of administering cytotoxic agents to cancer patients. Unfortunately, the maximum potential effect of these cytotoxic agents has been limited because of systemic toxicity and poor tumor perfusion. ... Full text Link to item Cite

Single-nucleotide polymorphisms in DNA bypass polymerase genes and association with breast cancer and breast cancer subtypes among African Americans and Whites.

Journal article Breast Cancer Res Treat · January 2015 DNA damage recognition and repair is a complex system of genes focused on maintaining genomic stability. Recently, there has been a focus on how breast cancer susceptibility relates to genetic variation in the DNA bypass polymerases pathway. Race-stratifie ... Full text Link to item Cite

NT-23PHASE 1/2A STUDY OF GLUTATHIONE PEGYLATED LIPOSOMAL DOXORUBICIN (2B3-101) IN BREAST CANCER PATIENTS WITH BRAIN METASTASES (BCBM) OR RECURRENT HIGH GRADE GLIOMAS (HGG)

Journal article Neuro-oncology · November 2014 BACKGROUND: Without active delivery across the blood-brain barrier, the efficacy of doxorubicin is limited in the treatment of brain tumors. 2B3-101 was developed as a brain-targeted doxorubicin product. In preclinical studies, 2B3-101 showed a 5-fold incr ... Cite

Age-specific changes in intrinsic breast cancer subtypes: a focus on older women.

Journal article Oncologist · October 2014 PURPOSE: Breast cancer (BC) is a disease of aging and the number of older BC patients in the U.S. is rising. Immunohistochemical data show that with increasing age, the incidence of hormone receptor-positive tumors increases, whereas the incidence of tripl ... Full text Link to item Cite

P08.032B3-101, GLUTATHIONE PEGYLATED LIPOSOMAL DOXORUBICIN, IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMAS AND BREAST CANCER BRAIN METASTASES

Journal article Neuro-oncology · September 2014 BACKGROUND: Without active delivery across the blood-brain barrier (BBB), efficacy of doxorubicin in intracranial tumors is limited. Glutathione pegylated liposomal doxorubicin (2B3-101) was developed as a brain-targeted chemotherapy. In rats treated with ... Cite

TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.

Journal article Breast Cancer Res Treat · August 2014 Nearly half of patients with advanced triple negative breast cancer (TNBC) develop brain metastases (BM) and most will also have uncontrolled extracranial disease. This study evaluated the safety and efficacy of iniparib, a small molecule anti-cancer agent ... Full text Link to item Cite

Breast cancer brain metastases: evidence for neuronal-like adaptation in a 'breast-to-brain' transition?

Journal article Breast Cancer Res · May 6, 2014 Brain metastases remain a significant challenge in the treatment of breast cancer patients due to the unique environment posed by the central nervous system. A better understanding of the biology of breast cancer cells that have metastasized to the brain i ... Full text Link to item Cite

TBCRC 018: Phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases

Journal article Breast Cancer Research and Treatment · January 1, 2014 Nearly half of patients with advanced triple negative breast cancer (TNBC) develop brain metastases (BM) and most will also have uncontrolled extracranial disease. This study evaluated the safety and efficacy of iniparib, a small molecule anti-cancer agent ... Full text Cite

αB-crystallin: a novel regulator of breast cancer metastasis to the brain.

Journal article Clin Cancer Res · January 1, 2014 PURPOSE: Basal-like breast tumors are typically (ER/PR/HER2) triple-negative and are associated with a high incidence of brain metastases and poor clinical outcomes. The molecular chaperone αB-crystallin is predominantly expressed in triple-negative breast ... Full text Link to item Cite

New targets for triple-negative breast cancer.

Journal article Oncology (Williston Park) · September 2013 Triple-negative breast cancer (TNBC) lacks the three most commonly targeted receptors in human breast cancer--the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)/neu--and it is associated with an aggr ... Link to item Cite

Breast cancer in adolescents and young adults: a review with a focus on biology.

Journal article J Natl Compr Canc Netw · September 1, 2013 Breast cancer is a substantial contributor to adolescent and young adult (AYA) malignancies, defined as a diagnosis of cancer between the ages of 15 and 39. In the United States, 6.6% of breast cancer cases are diagnosed among women younger than 40 years. ... Full text Link to item Cite

The management of early-stage and metastatic triple-negative breast cancer: a review.

Journal article Hematol Oncol Clin North Am · August 2013 Triple-negative breast cancer (TNBC), defined as lacking expression of the estrogen receptor, progesterone receptor, and HER2, comprises approximately 15% of incident breast cancers and is over-represented among those with metastatic disease. There are sev ... Full text Link to item Cite

Molecular characterization of basal-like and non-basal-like triple-negative breast cancer.

Journal article Oncologist · 2013 Triple-negative (TN) and basal-like (BL) breast cancer definitions have been used interchangeably to identify breast cancers that lack expression of the hormone receptors and overexpression and/or amplification of HER2. However, both classifications show s ... Full text Link to item Cite

Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer.

Journal article PLoS One · 2013 INTRODUCTION: Breast cancer brain metastases (BCBM) are a challenging consequence of advanced BC. Nanoparticle agents, including liposomes, have shown enhanced delivery to solid tumors and brain. We compared pharmacokinetics (PK) and efficacy of PEGylated ... Full text Link to item Cite

Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse.

Journal article Breast Cancer Res Treat · April 2012 The ability to predict metastatic potential could be of great clinical importance, however, it is uncertain if predicting metastasis to specific vital organs is feasible. As a first step in evaluating metastatic predictions, we analyzed multiple primary tu ... Full text Link to item Cite

Treatment of Breast Cancer Brain Metastases.

Journal article Curr Breast Cancer Rep · March 1, 2012 Approximately 10% to 15% of women with metastatic breast cancer will develop brain metastases. Treatment options for these women remain limited, particularly at the time of central nervous system (CNS) relapse following completion of initial CNS-directed t ... Full text Link to item Cite

Triple-negative breast cancer: an update on neoadjuvant clinical trials.

Journal article Int J Breast Cancer · 2012 Triple-negative breast cancer (TNBC) is an aggressive malignancy with a poor prognosis despite the high rates of response to chemotherapy. This scenario highlights the need to develop novel therapies and/or treatment strategies to reduce the mortality asso ... Full text Link to item Cite

An Integrated Approach to the Prediction of Chemotherapeutic Response in Patients with Breast Cancer

Journal article PLoS ONE · December 1, 2011 Background: A major challenge in oncology is the selection of the most effective chemotherapeutic agents for individual patients, while the administration of ineffective chemotherapy increases mortality and decreases quality of life in cancer patients. Thi ... Full text Cite

Young women with locally advanced breast cancer who achieve breast conservation after neoadjuvant chemotherapy have a low local recurrence rate.

Journal article Am Surg · July 2011 Women with locally advanced breast cancer (LABC) who are breast conservation (BCT) candidates after neoadjuvant chemotherapy have the best long-term outcome and low local-regional recurrence (LRR) rates. However, young women are thought to have a higher ri ... Link to item Cite

The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases.

Journal article Cancer · April 15, 2011 BACKGROUND: Brain metastases (BM) arising from triple-negative breast cancer (TNBC) portend a poor prognosis. TNBC is more common in premenopausal and African-American (AA) patients; both of these characteristics also confer a poor prognosis. In a single-i ... Full text Link to item Cite

Stratifying triple-negative breast cancer: which definition(s) to use?

Journal article Breast Cancer Res · April 1, 2011 Triple-negative breast cancers (TNBC) have increased rates of pathologic complete response following neoadjuvant chemotherapy, yet have poorer prognosis compared with non-TNBC. Known as the triple-negative paradox, this highlights the need to dissect the b ... Full text Link to item Cite

Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases.

Journal article Breast Cancer Res · 2011 INTRODUCTION: Activation status of the phosphatidylinositol 3-kinase (PI3K) pathway in breast cancer brain metastases (BCBMs) is largely unknown. We examined expression of phospho(p)-AKT, p-S6, and phosphatase and tensin homologue (PTEN) in BCBMs and their ... Full text Link to item Cite

Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer.

Journal article Clin Cancer Res · October 1, 2010 In contrast to endocrine-sensitive and human epidermal growth factor receptor 2 (HER2)-positive breast cancer, novel agents capable of treating advanced triple-negative breast cancer (TNBC) are lacking. Poly(ADP-ribose) polymerase (PARP) inhibitors are eme ... Full text Link to item Cite

A nationwide survey of oncologists regarding treatment-related infertility and fertility preservation in female cancer patients.

Journal article Fertil Steril · October 2010 OBJECTIVE: To survey oncologists regarding their knowledge and practice patterns concerning fertility preservation for female cancer patients. DESIGN: An online survey was sent to oncologists at cancer centers ranked by U.S. News & World Report. SETTING: O ... Full text Link to item Cite

Immune signatures predict prognosis in localized cancer.

Journal article Cancer Invest · August 2010 The host immune response can impact cancer growth, prognosis, and response to therapy. In colorectal cancer, the presence of cells involved with T-cell-mediated adaptive immunity predicts survival better than the current staging method. We used the express ... Full text Link to item Cite

GnRH: Authors' response

Journal article Journal of Women S Health · September 1, 2009 Full text Cite

Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.

Journal article Clin Breast Cancer · June 2009 Of the estimated 1 million cases of breast cancer diagnosed annually worldwide, it is estimated that over 170,000 will harbor the triple-negative (estrogen receptor/progesterone receptor/HER2-negative) phenotype. Most, though not all, triple-negative breas ... Full text Link to item Cite

Breast cancer before age 40 years.

Journal article Semin Oncol · June 2009 Approximately 7% of women with breast cancer are diagnosed before the age of 40 years, and this disease accounts for more than 40% of all cancer in women in this age group. Survival rates are worse when compared to those in older women, and multivariate an ... Full text Link to item Cite

Pilot survey of oncologists regarding treatment-related infertility and fertility preservation in female cancer patients.

Journal article J Reprod Med · April 2009 OBJECTIVE: To conduct a quantitative survey that focuses on oncologists' practice patterns and attitudes surrounding treatment-related infertility and fertility preservation, specifically among women of reproductive age. STUDY DESIGN: A 19-item survey was ... Link to item Cite

Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis.

Journal article J Womens Health (Larchmt) · March 2009 PURPOSE: Treatment with cyclophosphamide (CYC) confers up to a 40% risk of ovarian failure in women of reproductive age. The use of GnRH agonists (GnRHa) to preserve ovarian function has been investigated in several small studies. We performed a systematic ... Full text Link to item Cite

An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer.

Journal article Breast Cancer Res · 2009 INTRODUCTION: Perhaps the major challenge in developing more effective therapeutic strategies for the treatment of breast cancer patients is confronting the heterogeneity of the disease, recognizing that breast cancer is not one disease but multiple disord ... Full text Link to item Cite

Understanding and treating triple-negative breast cancer.

Journal article Oncology (Williston Park) · October 2008 Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique molecular profile, aggressive behavior, distinct patte ... Link to item Cite

Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.

Journal article J Clin Oncol · July 10, 2008 PURPOSE: Breast cancer arising in young women is correlated with inferior survival and higher incidence of negative clinicopathologic features. The biology driving this aggressive disease has yet to be defined. PATIENTS AND METHODS: Clinically annotated, m ... Full text Link to item Cite

Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.

Journal article JAMA · April 2, 2008 CONTEXT: Gene expression profiling may be useful for prognostic and therapeutic strategies in breast carcinoma. OBJECTIVES: To demonstrate the value in integrating genomic information with clinical and pathological risk factors, to refine prognosis, and to ... Full text Link to item Cite

An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer.

Journal article PLoS One · April 2, 2008 BACKGROUND: A major challenge in oncology is the selection of the most effective chemotherapeutic agents for individual patients, while the administration of ineffective chemotherapy increases mortality and decreases quality of life in cancer patients. Thi ... Full text Open Access Link to item Cite

Age-specific differences in oncogenic pathway deregulation seen in human breast tumors.

Journal article PLoS One · January 2, 2008 PURPOSE: To define the biology driving the aggressive nature of breast cancer arising in young women. EXPERIMENTAL DESIGN: Among 784 patients with early stage breast cancer, using prospectively-defined, age-specific cohorts (young or=6 ... Full text Open Access Link to item Cite

A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer.

Journal article Cancer Invest · 2008 BACKGROUND: Premenopausal women treated for early stage breast cancer (ESBC) are at risk for chemotherapy-related amenorrhea (CRA). Prospectively-validated, predictive markers of CRA are needed. PATIENTS AND METHODS: Premenopausal women with ESBC and plann ... Full text Link to item Cite

Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer.

Journal article J Clin Oncol · October 1, 2007 PURPOSE: Standard treatment for advanced non-small-cell lung cancer (NSCLC) includes the use of a platinum-based chemotherapy regimen. However, response rates are highly variable. Newer agents, such as pemetrexed, have shown significant activity as second- ... Full text Link to item Cite

Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.

Journal article J Transl Med · September 6, 2007 BACKGROUND: The HER2-inhibiting antibody trastuzumab, in combination with chemotherapy, significantly improves survival of women with resected, HER2-overexpressing breast cancers, but is associated with toxicities including a risk of cardiomyopathy. Additi ... Full text Link to item Cite

The Extermann article reviewed

Journal article Oncology · December 1, 2006 Cite